New antibody therapy tested for long-term safety in immune-deficient patients
NCT ID NCT06076642
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests the long-term safety of TAK-881, a subcutaneous immunoglobulin treatment, in 53 adults and children with primary immunodeficiency diseases (PIDD) who completed a prior study. Participants receive regular infusions every 2-4 weeks and are monitored for side effects and infection rates. The goal is to see if this treatment remains safe and well-tolerated over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-881 (immune globulin with hyaluronidase)
- What this could lead to
- If successful, this could confirm a safe, convenient long-term treatment option to help people with PIDD fight infections.
- What could go wrong
- This is an extension study with no placebo group, so results are limited. Side effects like infusion reactions or infections may still occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PID) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus Universitetshospital
Aarhus, 8200, Denmark
-
Allergy & Asthma Clinical Research
Walnut Creek, California, 94598, United States
-
Allergy Partners of North Texas
Dallas, Texas, 75230, United States
-
Allergy, Asthma and Immunology Center
Tulsa, Oklahoma, 74136, United States
-
Central Georgia Infectious Disease Consultants
Macon, Georgia, 31201, United States
-
Duke Asthma, Allergy and Airway Center
Durham, North Carolina, 27705, United States
-
Fakultni nemocnice Motol a Homolka Ustav imunologie
Prague, 150 06, Czechia
-
General Hospital of Thessaloniki
Thessaloniki, 56429, Greece
-
Hospital Sant Joan de Deu Barcelona
Barcelona, 08950, Spain
-
Instytut Pomnik - Centrum Zdrowia Dziecka
Warsaw, 04-730, Poland
-
Klinika Deti a Dorastu - Odborne Ambulancie UNM a JLF UK
Martin, 036 01, Slovakia
-
Louisiana State University Health Science Center
New Orleans, Louisiana, 70118, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
NUDCH (National Institute of Childrens Diseases)
Bratislava, 833 40, Slovakia
-
National Jewish Medical And Research Center
Denver, Colorado, 80206-2761, United States
-
North Shore-Long Island Jewish Health Systems
Great Neck, New York, 11021, United States
-
OKIA s.r.o
Košice, 040 01, Slovakia
-
Osrodek Pediatryczny im. DR J. Korczaka, Wojewodzkie
Lodz, 90329, Poland
-
Rush University Medical Center-Allergy/ Immunology Center
Chicago, Illinois, 60612-3852, United States
-
Sneeze, Wheeze, & Itch Associates, LLC
Normal, Illinois, 61761, United States
-
University Hospital Brno
Brno, 62500, Czechia
-
University of California, Irvine Medical Sciences I
Irvine, California, 92697, United States
-
University of South Florida
St. Petersburg, Florida, 33701, United States
-
Uniwersyteckie Centrum Kliniczne (UCK)
Gdansk, 80-952, Poland
-
Wojskowy Instytut Medyczny Panstwowy Instytut
Warsaw, 04-141, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- VR goggles ease needle pain for kids with rare immune disorder
- Safety check: cuvitru under the microscope for immune deficiency patients
- New shot option for immune deficiency shows promise in early trial
- Lab study explores new ways to treat rare immune diseases
- New drug shows promise for long-term immune deficiency treatment